{
    "clinical_study": {
        "@rank": "35121", 
        "arm_group": {
            "arm_group_label": "The CoreValve\u2122 Evolut R TAV\u2122 system", 
            "arm_group_type": "Experimental", 
            "description": "CoreValve\u2122 Evolut R\u2122 System which consists of the Evolut R\u2122 Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R\u2122 Delivery Catheter System with Enveo InLine\u2122 Sheath, and EnVeo R\u2122 Loading System"
        }, 
        "brief_summary": {
            "textblock": "To assess the safety and clinical performance of the CoreValve\u2122 Evolut R\u2122 System."
        }, 
        "brief_title": "The Medtronic CoreValve\u2122 Evolut R\u2122 Clinical Study", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "detailed_description": {
            "textblock": "The study objectives are to assess the safety and clinical performance of the CoreValve\u2122\n      Evolut R\u2122 System in patients with severe symptomatic aortic stenosis who are considered at\n      high through extreme risk for surgical aortic valve replacement.   These objectives will be\n      accomplished by a prospective clinical study involving up to 60 implanted subjects among up\n      to six study centers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve\n             area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg\n             or maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram.\n\n          2. Estimated 30 day mortality risk of > 15% by study center Heart Team assessment,33 OR\n             at least two cardiovascular surgeons from the study center deny surgery because of\n             prohibitive operative risk, estimated to be a combined >50% risk of irreversible\n             mortality or morbidity.\n\n          3. Symptoms of aortic stenosis, and NYHA Functional Class II or greater.\n\n          4. The subject meets the legal minimum age to provide informed consent based on local\n             regulatory requirements, and has provided written informed consent as approved by the\n             EC/IRB of the respective clinical site.\n\n          5. The subject and the treating physician agree that the subject will return for all\n             required post-procedure follow-up visits.\n\n             Exclusion Criteria:\n\n             Clinical exclusion criteria:\n\n          6. Subject has been offered SAVR but has declined.\n\n          7. Any condition considered a contraindication for placement of a bioprosthetic valve\n             (e.g. subject is indicated for mechanical prosthetic valve).\n\n          8. Known hypersensitivity or contraindication to Nitinol.\n\n          9. Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), thrombocytopenia (platelet\n             count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or\n             hypercoagulable states.\n\n         10. Untreated clinically significant coronary artery disease requiring revascularization.\n\n         11. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF)\n             <20% by echocardiography, contrast ventriculography, or radionuclide\n             ventriculography.\n\n         12. End stage renal disease requiring chronic dialysis of creatinine clearance < 20\n             cc/min.\n\n         13. Ongoing sepsis, including active endocarditis.\n\n         14. Any condition considered a contraindication to extracorporeal assistance.\n\n         15. Any percutaneous coronary or peripheral interventional procedure with a bare metal\n             stent performed within 30 days prior to Heart Team assessment, or within six months\n             prior to Heart Team assessment for procedures with a drug eluting stents.\n\n         16. Symptomatic carotid or vertebral artery disease or successful treatment of carotid\n             stenosis within eight weeks of Heart Team Assessment .\n\n         17. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or\n             mechanical hemodynamic support.\n\n         18. Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or\n             transient ischemic attack (TIA).\n\n         19. Gastrointestinal (GI) bleeding that would preclude anticoagulation.\n\n         20. Subject refuses a blood transfusion.\n\n         21. Severe dementia (resulting in either inability to provide informed consent for the\n             study/procedure, prevents independent lifestyle outside of a chronic care facility,\n             or will fundamentally complicate rehabilitation from the procedure or compliance with\n             follow-up visits).\n\n         22. Estimated life expectancy of less than 12 months due to associated non-cardiac\n             co-morbid conditions.\n\n         23. Other medical, social, or psychological conditions that in the opinion of the\n             Investigator precludes the subject from appropriate consent or adherence to the\n             protocol required follow-ups exams.\n\n         24. Currently participating in an investigational drug or another device study (excluding\n             registries).\n\n         25. Evidence of an acute myocardial infarction \u226430 days before the index procedure.\n\n         26. Need for emergency surgery for any reason.\n\n         27. Liver failure (Child-C).\n\n         28. Subject is pregnant or breast feeding.\n\n             Anatomical exclusion criteria:\n\n         29. Pre-existing prosthetic heart valve in any position.\n\n         30. Mixed aortic valve disease (aortic stenosis with moderate or severe aortic\n             regurgitation).\n\n         31. Severe mitral regurgitation.\n\n         32. Severe tricuspid regurgitation.\n\n         33. Moderate or severe mitral stenosis.\n\n         34. Hypertrophic obstructive cardiomyopathy.\n\n         35. Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac\n             mass thrombus or vegetation.\n\n         36. Congenital bicuspid or unicuspid valve verified by echocardiography."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876420", 
            "org_study_id": "MDT10093773DOC"
        }, 
        "intervention": {
            "arm_group_label": "The CoreValve\u2122 Evolut R TAV\u2122 system", 
            "description": "CoreValve\u2122 Evolut R\u2122 System which consists of the Evolut R\u2122 Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R\u2122 Delivery Catheter System with Enveo InLine\u2122 Sheath, and EnVeo R\u2122 Loading System", 
            "intervention_name": "The CoreValve\u2122 Evolut R TAV\u2122 system", 
            "intervention_type": "Device", 
            "other_name": [
                "The CoreValve\u2122 Evolut R TAV\u2122 system is a recapturable transcatheter aortic valve implantation (TAVI) system comprised of the following three components:", 
                "1) CoreValve\u2122 Evolut R\u2122 Transcatheter Aortic Valve (Evolut R\u2122 TAV)", 
                "2) Enveo R\u2122 Delivery Catheter System (DCS) with Enveo InLine\u2122 Sheath", 
                "3) EnVeo R\u2122 Loading System (LS)"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 9, 2013", 
        "location": {
            "contact": {
                "email": "charles.boldt@medtronic.com", 
                "last_name": "Charles Boldt", 
                "phone": "763-514-9734", 
                "phone_ext": "49734"
            }, 
            "facility": {
                "address": {
                    "city": "Mounds View", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55112"
                }, 
                "name": "Medtronic, Inc."
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Medtronic CoreValve\u2122 Evolut R\u2122 Clinical Study", 
        "overall_contact": {
            "email": "charles.boldt@medtronic.com", 
            "last_name": "Charles Boldt", 
            "phone": "763-514-9734", 
            "phone_ext": "49734"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "All-cause mortality rate at 30 days", 
                "measure": "All-cause mortality rate at 30 days", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Stroke rate (disabling and non-disabling) at 30 days", 
                "measure": "Stroke rate (disabling and non-disabling) at 30 days", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Device success rate at 24 hours to seven days, defined as:\nAbsence of procedural mortality, AND\nCorrect positioning of a single prosthetic heart valve into the proper anatomical location, AND\nIntended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity < 3 m/sec), AND absence of moderate or severe prosthetic valve regurgitation.\nThe percentage of subjects with no more than mild aortic regurgitation at early post procedure echocardiogram (24 hours through seven days).", 
                "measure": "Device success rate at 24 hours to seven days", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours to seven days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876420"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)", 
                "measure": "Event rate of the VARC II Combined Safety Endpoint at 30 days", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Event rates of the individual components of the VARC II composite safety endpoint at 30 days", 
                "measure": "Event rates of the individual components of the VARC II composite safety endpoint at 30 days", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Recapture success rate (when attempted), where successful recapture is defined as Evolut R\u2122 TAV (including the frame) is fully resheathed into the capsule of the delivery catheter, as verified by fluoroscopy.", 
                "measure": "Recapture success rate (when attempted), where successful recapture is defined as Evolut R\u2122 TAV (including the frame) is fully resheathed into the capsule of the delivery catheter, as verified by fluoroscopy.", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Mean prosthetic valve gradient\nEffective orifice area\nDegree of prosthetic valve regurgitation (transvalvular, paravalvular, and total)", 
                "measure": "Hemodynamic performance metrics at 30 days by Doppler echocardiography", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Medtronic Cardiovascular", 
        "sponsors": {
            "collaborator": {
                "agency": "Medtronic", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medtronic Cardiovascular", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}